title: Differential expression of the heat shock protein 70 in the histological compartments of nephroblastomas.
abstract: Nephroblastomas (Wilms' tumors) are curable with survival rates above 80%. Nevertheless, some tumors fail to respond to therapy and those patients have a poor prognosis. Prognostic factors for nephroblastomas have still not been satisfactorily explored. In an effort to unravel molecular markers for non-responding nephroblastomas, we investigated by means of immunohistochemistty the expression of heat-shock protein 70 (HSP70) in formalin-fixed and paraffin-embedded tissue samples from 32 children afflicted with nephroblastoma. The results were validated using real-time RT-PCR. HSP70 expression was confined to blastemal and epithelial components, while the tumor stroma was negative. HSP70 expression was greater, if the tumors had been chemotherapeutically treated prior to operation, indicating that cytostatic drugs induce HSP70. Furthermore, high HSP70 expression was confined to tumors from children who survived, whereas tumors from dead patients were negative or weakly-positive for HSP70. Though the number of cases analyzed was small, they provide an indication that HSP70 expression may be of prognostic value.
authors.affiliation: University of Göttingen, Germany. efferth@vcrp.de
authors.forename: T
authors.initials: T
authors.lastname: Efferth
authors.forename: H G
authors.initials: HG
authors.lastname: Schulten
authors.forename: P
authors.initials: P
authors.lastname: Thelen
authors.forename: M E
authors.initials: ME
authors.lastname: Bode
authors.forename: A J
authors.initials: AJ
authors.lastname: Beniers
authors.forename: B
authors.initials: B
authors.lastname: Granzen
authors.forename: R H
authors.initials: RH
authors.lastname: Ringert
authors.forename: R
authors.initials: R
authors.lastname: Mertens
authors.forename: O
authors.initials: O
authors.lastname: Gefeller
authors.forename: G
authors.initials: G
authors.lastname: Jakse
authors.forename: L
authors.initials: L
authors.lastname: Fuzesi
mesh_terms: D000293:Adolescent; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000032:analysis*; D002648:Child; D002675:Child, Preschool; D003131:Combined Modality Therapy; D003199:Computer Systems; D003609:Dactinomycin / Q000008:administration & dosage; D019008:Drug Resistance, Neoplasm; D004847:Epithelial Cells / Q000737:chemistry; D015972:Gene Expression Regulation, Neoplastic; D018840:HSP70 Heat-Shock Proteins / Q000032:analysis / Q000096:biosynthesis* / Q000235:genetics; D006801:Humans; D007223:Infant; D007680:Kidney Neoplasms / Q000188:drug therapy / Q000378:metabolism* / Q000401:mortality / Q000473:pathology / Q000601:surgery; D009363:Neoplasm Proteins / Q000032:analysis / Q000096:biosynthesis* / Q000235:genetics; D009367:Neoplasm Staging; D014411:Neoplastic Stem Cells / Q000737:chemistry; D011379:Prognosis; D020133:Reverse Transcriptase Polymerase Chain Reaction; D017154:Stromal Cells / Q000737:chemistry; D016019:Survival Analysis; D016896:Treatment Outcome; D014750:Vincristine / Q000008:administration & dosage; D009396:Wilms Tumor / Q000188:drug therapy / Q000378:metabolism* / Q000401:mortality / Q000473:pathology / Q000601:surgery
chemical_list: D014408:Biomarkers, Tumor; D018840:HSP70 Heat-Shock Proteins; D009363:Neoplasm Proteins; D003609:Dactinomycin; D014750:Vincristine